Ectopic Pregnancies Clinical Trial
Official title:
Single Determination of Serum Activin A and Inhibin A in Predicting the Outcome of Pregnancies of Unknown Location (PUL) After IVF and Oocyte Donation.
The purpose of this study is to determine the predictive value of a single serum determination of activin A and inhibin A for the prognosis of ectopic pregnancy after in Vitro Fertilization (IVF) cycles, in both native and donated oocytes.
Ectopic pregnancy (EP) is one of the most common pathologies seen in emergency gynaecology
practice. Early diagnostic of this situation is a clinical objective because it remains an
important cause of maternal morbidity and mortality worldwide. Currently, transvaginal
ultrasound scan (TVS) allow ascertain the location of the pregnancy. However, the diagnosis
of EP is complicated by a nonspecific clinical presentation and the inconclusive results in
some cases of transvaginal ultrasound at first presentation. For this reason several
biomarkers have been investigated to accurately detect the establishment of pregnancy and
predict its outcome as early as possible.
These biomarkers include: markers of abnormal embryo/trophoblast growth (β-subunit of HCG,
Activin A, etc), markers of abnormal corpus luteum function (progesterone, inhibin A, etc),
markers of a growing pregnancy in the Fallopian tube (creatine kinase, vascular endothelial
growth factor, etc), markers of inflammation and peritoneal irritation (cancer antigen 125,
interleukin-6, etc), and uterine markers of normal implantation (leukaemia inhibitory factor
and glycodelin). Β-HCG and progesterone are usually used in clinical practice and activin A
and inhibin A have recently shown promising results.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03138694 -
Adnexal Mass After Methotrexate Treatment for Ectopic Pregnancies
|
N/A |